

BREAST CANCER SESSION


1 NOVEMBER 2025
(SATURDAY)


08:30 – 16:10 HRS
UAE TIME


IN-PERSON


AL RAS 3

SESSION 1:

Chairpersons: Shona Nag, India | Dima Abdul Jabbar, UAE | Mouza Al Ameri, UAE

08:30 – 08:45	Opening Remarks
08:45 – 09:00	What worked and What didn't in Breast Cancer in 2025 Stephen Johnston, UK
09:00 – 09:15	De-escalating Surgery in Early-Stage Breast Cancer Nita Nair, India
09:15 – 09:30	Breaking New Grounds in HR+ HER2- eBC - <i>Satellite Symposium by Novartis</i> Shaheenah Dawood, UAE
09:30 – 09:50	Pushing Boundaries: Verzenio's Breakthrough in Early Breast Cancer Treatment - <i>Satellite Symposium by Lilly</i> Stephen Johnston, UK
09:50 – 10:30	Round Table Discussion: Challenging Cases in High-Risk HR+ve HER2-ve Early-Stage Breast Cancer Moderator: Shona Nag, India Panelists: Stephen Johnston, UK Hamdy Abdul Azim, Egypt Francois-Clement Bidard, France Husam Marashi, UAE Dorai Ramanathan, UAE Cherian Thampy, UAE Riyadh Bendardaf, UAE Stephen Grobmyer, UAE Abdulrahman Sumaida, UAE Ahlam Mohammad, Qatar Devan Moodley, South Africa
10:30 – 10:35	Q & A
10:35 – 10:55	Coffee Break

SESSION 2:

Chairpersons: Falah Al Khatib, UAE | Patrizia Porcu, UAE | Stephen Grobmyer, UAE

10:55 – 11:10	Evolving landscape of ADCs in Breast Cancer: A Look into the Future Giuseppe Curigiano, Italy
11:10 – 11:35	Managing Hormone Receptive + HER2 Negative Metastatic Breast Cancer in a Molecularly Driven Era Francois Clement- Bedard, France
11:35 – 11:50	Targeting the AKT Pathway: Redefining Outcomes in HR+/HER2– mBC - <i>Satellite Symposium by AstraZeneca</i> Javier Cortes, Spain
11:50 – 12:10	Pushing Boundaries: Verzenio's Expanding Role in Metastatic Breast Cancer Patients - <i>Satellite Symposium by Lilly</i> Stephen Johnston, UK

BREAST CANCER SESSION

12:10 – 12:25	Improving Survival and Quality of Life in HR+ HER2- mBC - <i>Satellite Symposium by Novartis</i> Maroun El Khoury, UAE
12:25 – 12:40	Management of HER2 Positive Metastatic Breast Cancer in 2025 Hamdy Abdul Azim, Egypt
12:40 – 13:10	Panel Discussion: Personalizing HER 2+ Breast Cancer Management: Integrating New Data Across the Treatment Continuum - <i>Supported by Roche</i> Moderator: Shaheenah Dawood, UAE Panelists: Husam Marashi, UAE Nouri Bennini, UAE Hassan Shahryar, UAE Diaeddine Trad, UAE
13:10 – 14:15	Lunch Break
SESSION 3: Chairpersons: Khalifa AlKaabi, UAE Archana Shetty, UAE Ankur Bahl, India	
14:15 – 14:55	Independent Medical Education - <i>Supported by Gilead Sciences</i> (5 mins) Welcome Baseline Pulse check Shaheenah Dawood, UAE (15 mins) Clinical Dive: What's new and what's next in mTNBC Javier Cortes, Spain (20 mins) Peer Conversation what would you do: Rethinking mTNBC algorithm Panel Discussion: Shaheenah Dawood, UAE Javier Cortes, Spain Dalia Elshorbagy, UAE Sonia Otsmane, UAE Fathi Azribi, UAE
14:55 – 15:10	Novel Therapeutics beyond Immune Therapy in the Management of Triple Negative Breast Cancer Javier Cortes, Spain
15:10 – 15:35	Moving from Assumed to Proven Chemotherapy Benefit in the Management of Early-Stage BC Moderator: Shaheenah Dawood Panelists: Javier Cortes, Spain Stephen Johnston, UK Devan Moodley, South Africa Maroun El Khoury, UAE Dorai Ramanathan, UAE
15:35 – 16:05	Round Table Discussion: Challenging Cases in HR+ve/HER2-ve Metastatic Breast Cancer Moderator: Nitesh Rohatgi, India Panelists: Amir Abdelazim, Kuwait Javier Cortes, Spain Stephen Johnston, UK Ahmed Saadeddin, KSA Hassan Ghazal, UAE Rham Zaki Ahmed, UAE Maha Al Sindi, Bahrain Devan Moodley, South Africa Jennifer Leong, Malaysia Abdul Rahman El Kinge, UAE
16:05 – 16:10	Closing Remarks

Please scan the back of your badge to access the latest program.

cancercongress.ae